Skip to main content
SpringerLink
Log in

FDG PET/CT versus somatostatin receptor PET/CT in TENIS syndrome: a systematic review and meta-analysis

  • Meta-Analysis
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Purpose

In patients with TENIS syndrome (Thyroglobulin-Elevated Negative Iodine Scintigraphy), PET/CT radiotracers, such FDG PET/CT and somatostatin analogs (SSTR PET/CT), can identify disease localization. Therefore, the objective of this paper is to compare the capability of identifying lesions in TENIS Syndrome using FDG PET/CT and SSTR PET/CT through a systematic review and meta-analysis.

Methodology

A literature search was performed in electronic databases until February 2020 to identify relevant studies on FDG and 68 Ga-somatostatin analogs tracers in patients with TENIS Syndrome.

Results

A total of 3551 abstracts reviewed from electronic databases and bibliographic references identified 13 candidates for the full-text analysis, and six articles were included in the qualitative and quantitative analyses. A total of 179 patients submitted to both SSTR PET/CT and FDG PET/CT to evaluate the performance of these radiotracers were analyzed. FDG PET/CT images identified significantly (p = 0.006) more patients with metastases when compared to SSTR PET/CT (143 vs. 103, respectively). Even though FDG PET/CT outperformed SSTR PET/CT, SSTR PET/CT was able to detect metastases in approximately 16% of FDG PET/CT negative cases.

Conclusion

FDG PET/CT has a higher capability to detect metastases than SSTR PET/CT in patients with TENIS Syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Traub-Weidinger T, Putzer D, von Guggenberg E et al (2015) Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging 42:1995–2001. https://doi.org/10.1007/s00259-015-3114-6

    Article  CAS  PubMed  Google Scholar 

  2. Pellegriti G, Frasca F, Regalbuto C et al (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:1–10. https://doi.org/10.1155/2013/965212

    Article  Google Scholar 

  3. Iñiguez-Ariza NM, Brito JP (2018) Management of low-risk papillary thyroid cancer. Endocrinol Metab 33:185. https://doi.org/10.3803/EnM.2018.33.2.185

    Article  Google Scholar 

  4. Lan W, Gege Z, Ningning L et al (2019) Negative remnant 99mTc-pertechnetate uptake predicts excellent response to radioactive iodine therapy in low- to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy. Ann Nucl Med 33:112–118. https://doi.org/10.1007/s12149-018-1314-4

    Article  CAS  PubMed  Google Scholar 

  5. Stokkel MPM, Duchateau CSJ, Dragoiescu C (2006) The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 50:78–87

    CAS  PubMed  Google Scholar 

  6. Avram AM, Rosculet N, Esfandiari NH et al (2019) Differentiated thyroid cancer outcomes after surgery and activity-adjusted 131I theragnostics. Clin Nucl Med 44:11–20. https://doi.org/10.1097/RLU.0000000000002321

    Article  PubMed  Google Scholar 

  7. Marcus C, Whitworth PW, Surasi DS et al (2014) PET/CT in the management of thyroid cancers. Am J Roentgenol 202:1316–1329. https://doi.org/10.2214/AJR.13.11673

    Article  Google Scholar 

  8. Chung JK, So Y, Lee JS et al (1999) Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40:986–992

    CAS  PubMed  Google Scholar 

  9. Wang W, Macapinlac H, Larson SM et al (1999) [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302. https://doi.org/10.1210/jcem.84.7.5827

    Article  CAS  PubMed  Google Scholar 

  10. Feine U, Lietzenmayer R, Hanke JP et al (1995) 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34:127–134

    Article  CAS  Google Scholar 

  11. Pisarek H, Stępień T, Kubiak R et al (2009) Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res 2:1. https://doi.org/10.1186/1756-6614-2-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Klagge A, Krause K, Schierle K et al (2010) Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 42:237–240. https://doi.org/10.1055/s-0029-1243636

    Article  CAS  PubMed  Google Scholar 

  13. Kundu P, Lata S, Sharma P et al (2014) Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: Comparison with 18F-FDG PET-CT. Eur J Nucl Med Mol Imaging 41:1354–1362. https://doi.org/10.1007/s00259-014-2723-9

    Article  CAS  PubMed  Google Scholar 

  14. Shinto A, Samuel G, Velayutham P et al (2015) Utility of 99m Tc-Hynic-TOC in 131I whole-body scan negative thyroid cancer patients with elevated serum thyroglobulin levels. World J Nucl Med 14:101. https://doi.org/10.4103/1450-1147.154229

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rodrigues M, Li S, Gabriel M et al (2006) 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab 91:3997–4000. https://doi.org/10.1210/jc.2006-0825

    Article  CAS  PubMed  Google Scholar 

  16. Middendorp M, Selkinski I, Happel C et al (2010) Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging 54:76–83

    CAS  PubMed  Google Scholar 

  17. Le PS, Konopka T, Gacquer D et al (2015) Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases. Endocr Relat Cancer 22:205–216. https://doi.org/10.1530/ERC-14-0351

    Article  CAS  Google Scholar 

  18. Chmielik E, Rusinek D, Oczko-Wojciechowska M et al (2018) Heterogeneity of thyroid cancer. Pathobiology 85:117–129. https://doi.org/10.1159/000486422

    Article  PubMed  Google Scholar 

  19. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13

    Article  PubMed  PubMed Central  Google Scholar 

  20. Pauwels E, Cleeren F, Bormans G, Deroose CM (2018) Somatostatin receptor PET ligands-the next generation for clinical practice. Am J Nucl Med Mol Imaging 8:311–331

    CAS  PubMed  PubMed Central  Google Scholar 

  21. National Institute of Health (2020) NIH Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 1 May 2020.

  22. Rücker G, Schwarzer G, Carpenter J, Olkin I (2009) Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 28:721–738. https://doi.org/10.1002/sim.3511

    Article  PubMed  Google Scholar 

  23. Wallace BC, Dahabreh IJ, Trikalinos TA et al (2012) Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 49:1–15. https://doi.org/10.18637/jss.v049.i05

    Article  Google Scholar 

  24. Binse I, Poeppel TD, Ruhlmann M et al (2016) 68Ga-DOTATOC PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med 57:1512–1517. https://doi.org/10.2967/jnumed.115.171942

    Article  CAS  PubMed  Google Scholar 

  25. Torun N, Erhmamci S, Reyhan M et al (2018) The clinic role of FDG-PET/CT and Ga68-DOTATATE PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole body scan and elevated serum thyroglobulin level. Eur Assoc Nucl Med. https://doi.org/10.1007/s00259-018-4148-3

    Article  Google Scholar 

  26. Versari A, Sollini M, Frasoldati A et al (2014) Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 24:715–726. https://doi.org/10.1089/thy.2013.0225

    Article  CAS  PubMed  Google Scholar 

  27. Druckenthaner M, Schwarzer C, Ensinger C et al (2007) Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept 138:32–39. https://doi.org/10.1016/j.regpep.2006.08.005

    Article  CAS  PubMed  Google Scholar 

  28. Wang Y, Wang W, Jin K et al (2017) Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett 13:1165–1174. https://doi.org/10.3892/ol.2017.5591

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Antunes P, Ginj M, Zhang H et al (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993. https://doi.org/10.1007/s00259-006-0317-x

    Article  CAS  PubMed  Google Scholar 

  30. Ganly I, Nixon IJ, Wang LY et al (2015) Survival from differentiated thyroid cancer: What has age got to do with it? Thyroid 25:1106–1114. https://doi.org/10.1089/thy.2015.0104

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kauffmann RM, Hamner JB, Ituarte PHG, Yim JH (2018) Age greater than 60 years portends a worse prognosis in patients with papillary thyroid cancer: Should there be three age categories for staging? BMC Cancer 18:1–10. https://doi.org/10.1186/s12885-018-4181-4

    Article  Google Scholar 

  32. Nilubol N, Zhang L, Kebebew E (2013) Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid 23:695–702. https://doi.org/10.1089/thy.2012.0269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Katoh H, Yamashita K, Enomoto T, Watanabe M (2015) Annals of clinical pathology classification and general considerations of thyroid cancer. Ann Clin Pathol 3:1–9

    Google Scholar 

  34. Araz M, Çayır D (2017) 18F-Fluorodeoxyglucose-positron emission tomography/computed tomography for other thyroid cancers: medullary, anaplastic, lymphoma and so forth. Mol Imaging Radionucl Ther 26:1–8. https://doi.org/10.4274/mirt.60783

    Article  PubMed  PubMed Central  Google Scholar 

  35. Carmona Matos DM, Jang S, Hijaz B et al (2019) Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers. Surgery (United States) 165:64–68. https://doi.org/10.1016/j.surg.2018.05.077

    Article  Google Scholar 

  36. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. J Clin Endocrinol Metab 102:1020–1031. https://doi.org/10.1210/jc.2016-3284

    Article  PubMed  Google Scholar 

  37. Poeppel TD, Binse I, Petersenn S et al (2013) Differential Uptake of 68Ga-DOTATOC and 68Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors. Springer, Berlin, pp 353–371. https://doi.org/10.1007/978-3-642-27994-2_18

    Book  Google Scholar 

Download references

Funding

None to declare.

Author information

Authors and Affiliations

  1. Real Hospital Português de Beneficência em Pernambuco, Real Nuclear, Avenida Portugal, no. 163, Paissandu, Recife, PE, 52010-010, Brazil

    Felipe Alves Mourato, Maria Amorim Almeida, Ana Emília Teixeira Brito, Aline Lopes Garcia Leal & Paulo Almeida Filho

  2. Division of Nuclear Medicine, University of Campinas (UNICAMP), Rua Tessália Vieira de Camargo, 126. Cidade Universitária Zeferino Vaz, Campinas, SP, 13083-887, Brazil

    Elba Etchebehere

Authors
  1. Felipe Alves Mourato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Amorim Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Emília Teixeira Brito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aline Lopes Garcia Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paulo Almeida Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elba Etchebehere
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elba Etchebehere.

Ethics declarations

Conflict of interest

None to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mourato, F.A., Almeida, M.A., Brito, A.E.T. et al. FDG PET/CT versus somatostatin receptor PET/CT in TENIS syndrome: a systematic review and meta-analysis. Clin Transl Imaging 8, 365–375 (2020). https://doi.org/10.1007/s40336-020-00390-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-020-00390-0

Keywords

Search

Navigation